GeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 3,728 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,728 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total transaction of $363,890.08. Following the sale, the chief financial officer directly owned 44,945 shares of the company’s stock, valued at approximately $4,387,081.45. The trade was a 7.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, September 9th, Kevin Feeley sold 1,285 shares of GeneDx stock. The shares were sold at an average price of $84.22, for a total transaction of $108,222.70.

GeneDx Price Performance

WGS stock opened at $101.10 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.06 and a current ratio of 3.30. The business has a 50-day simple moving average of $77.73 and a two-hundred day simple moving average of $67.34. The company has a market capitalization of $3.01 billion, a P/E ratio of -27.77 and a beta of 1.99. GeneDx Holdings Corp. has a 52-week low of $32.21 and a 52-week high of $170.87.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.20. GeneDx had a positive return on equity of 4.12% and a negative net margin of 23.41%.The firm had revenue of $114.44 million during the quarter, compared to the consensus estimate of $111.01 million. During the same period in the prior year, the business posted $0.36 earnings per share. Research analysts expect that GeneDx Holdings Corp. will post -0.41 EPS for the current fiscal year.

Institutional Trading of GeneDx

A number of institutional investors and hedge funds have recently modified their holdings of WGS. Main Management ETF Advisors LLC boosted its position in GeneDx by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock worth $2,037,000 after purchasing an additional 160 shares during the last quarter. Strs Ohio grew its stake in GeneDx by 8.7% in the 1st quarter. Strs Ohio now owns 2,500 shares of the company’s stock valued at $161,000 after purchasing an additional 200 shares during the period. Ramirez Asset Management Inc. bought a new stake in GeneDx in the fourth quarter worth about $33,000. ProShare Advisors LLC raised its position in GeneDx by 8.0% in the fourth quarter. ProShare Advisors LLC now owns 3,467 shares of the company’s stock worth $451,000 after acquiring an additional 257 shares during the period. Finally, Pictet Asset Management Holding SA increased its stake in shares of GeneDx by 12.9% during the 1st quarter. Pictet Asset Management Holding SA now owns 3,300 shares of the company’s stock worth $212,000 after purchasing an additional 378 shares during the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

WGS has been the subject of a number of analyst reports. Weiss Ratings raised GeneDx from a “sell (e+)” rating to a “sell (d)” rating in a research report on Tuesday, August 4th. Wall Street Zen raised shares of GeneDx from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Piper Sandler reiterated an “overweight” rating and issued a $63.00 target price (up from $50.00) on shares of GeneDx in a research note on Tuesday, June 23rd. TD Cowen reiterated a “buy” rating on shares of GeneDx in a report on Wednesday, July 15th. Finally, Zacks Research raised shares of GeneDx from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, GeneDx currently has an average rating of “Moderate Buy” and a consensus target price of $89.57.

About GeneDx

GeneDx Holdings Corp., doing business as GeneDx, is a healthcare company focused on genetic testing and genomic diagnostics. The company provides testing designed to help healthcare professionals diagnose rare and inherited conditions, guide clinical management, and support research into genetic disease.

Its offerings include whole exome and whole genome sequencing, targeted genetic tests, chromosomal microarray analysis, and other tests used to identify disease-causing genetic variants.